Peter Jay Hotez, MD, PhD
Department or Service
- Texas Medical Center
Director, Center for Vaccine Development
Texas Children's Hospital
Endowed Chair in Tropical Pediatrics, Texas Children's Hospital
Dean for the National School of Tropical Medicine, Baylor College of Medicine
Professor, Departments of Pediatrics and Molecular Virology & Microbiology, Baylor College of Medicine
Faculty Fellow, Hagler Institute for Advanced Study at Texas A&M University, College Station, TX
University Professor, Department of Biology, Baylor University, Waco, TX
|Weill Cornell Medical College, New York, NY||medical school||Medical Doctor||1987|
|The Rockefeller University, New York, NY||PhD||Doctor of Philosophy||1986|
Coronavirus Vaccine Development Program - COVID-19 is a highly transmissible with an estimated reproductive number (R0) of 2.2, a mean incubation period of 5.8 days and transmitted from infected individuals with or without symptoms. High transmissibility means that the control of this viral infection will be challenging without the prospect of a vaccine.
Human Hookworm Vaccine Initiative - Texas Children's Hospital Center for Vaccine Development - Development of a vaccine for the more than 400 million people suffering from hookworm infection in the world today. Vaccine currently in phase 1 clinical trials in Brazil and Gabon.
Schistosomiasis Vaccine Initiative - Texas Children's Hospital Center for Vaccine Development - Schistosomiasis afflicts over 200 million people around the globe and is the deadliest disease among the seven most prevalent NTDs, killing an estimated 280,000 people annually. Our vaccine is entering phase 1 clinical trials.
Chagas Disease and Leishmaniasis Vaccine Initiatives - Texas Children's Hospital Center for Vaccine Development - A project for the selection and discovery of antigens appropriate to advance into the development process of new vaccines to combat Chagas disease (American trypanosomiasis) and leishmaniasis.
SARS Vaccine Development Program - Texas Children's Hospital Center for Vaccine Development - A new vaccine to prevent severe acute respiratory syndrome (SARS). A prototype RBD219 N1 vaccine is entering scale-up process development
Multivalent Anthelmintic Vaccine Discovery Program - Texas Children's Hospital Center for Vaccine Development - A panhelmintic vaccine to prevent ascariasis (roundworm) and trichuris (whipworm), soil-transmitted helminths afflicting hundreds of millions of people around the world
View News Articles:
|James A. Baker III Institute for Public Policy, Rice University, Houston, TX||Fellow in Disease and Poverty|
|PLOS Neglected Tropical Diseases||Founding Editor in Chief|